目的 探讨葛根素注射液联合康柏西普眼用注射液治疗非增殖期糖尿病视网膜病变的临床疗效。方法 选取2019年12月—2022年6月秦皇岛市第二医院收治的98例糖尿病视网膜病变患者，按照随机数字表法将所有患者分为对照组和治疗组，每组各49例。对照组使用康柏西普眼用注射液治疗，在角膜缘4 mm处进针4 mm，一次性缓慢注入康柏西普眼用注射液，每眼0.5 mg。治疗组在对照组基础上静脉滴注葛根素注射液，400 mg/次，1次/d，10 d为1个疗程，连续3个疗程。两组在治疗30 d后统计疗效。观察两组的临床疗效，比较两组患者视力、眼部体征和血清指标。结果 治疗后，治疗组的总有效率为87.76%，明显高于对照组的总有效率71.43%，组间比较差异有统计学意义（P＜0.05）。治疗后，两组的最佳矫正视力（BCVA）高于治疗前（P＜0.05），且治疗组的BCVA较对照组更高（P＜0.05）。治疗后，两组的黄斑中心凹厚度（CMT）、出血斑面积、视野灰度值低于治疗前（P＜0.05）；治疗后，治疗组的CMT、出血斑面积、视野灰度值低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组的血清胱抑素C（Cys-C）、转化生长因子-β₁（TGF-β₁）、同型半胱氨酸（Hcy）水平低于治疗前（P＜0.05）；治疗组的血清Cys-C、TGF-β₁、Hcy水平低于对照组，差异有统计学意义（P＜0.05）。结论 葛根素注射液联合康柏西普眼用注射液治疗糖尿病视网膜病变的疗效确切，能改善患者视力，减轻眼部体征，降低血清Cys-C、TGF-β₁、Hcy水平，且安全性良好。

Objective To investigate the clinical efficacy of Puerarin Injection combined with Conbercept Ophthalmic Injection in treatment of non-proliferative diabetic retinopathy. Methods Patients (98 cases) with non-proliferative diabetic retinopathy in the Second Hospital of Qinhuangdao from December 2019 to June 2022 were divided into control and treatment groups according to the random number table method, and each group had 49 cases. Patients in the control group were given Conbercept Ophthalmic Injection, inject 4 mm at 4 mm of the corneal limbus, and slowly inject Conbercept Ophthalmic Injection once, 0.5 mg per eye. Patients in the treatment group were iv administered with Puerarin Injection on the basis of the control group, 400 mg/time, once daily, 10 days as a course of treatment, for 3 consecutive courses. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and visual acuity, ocular sign, serum indexes levels in two groups were compared. Results After treatment, the total effective rate of the treatment group was 87.76%, which was significantly higher than that of the control group (71.43%), with a statistically significant difference (P < 0.05). After treatment, the BCVA of two groups was higher than that before treatment (P < 0.05), and the BCVA of the treatment group was higher than that of the control group (P < 0.05). After treatment, the CMT, the area of bleeding spot, and the gray value of visual field in two groups were lower than those before treatment (P < 0.05). After treatment, the CMT, the area of bleeding spot, and the gray value of visual field in the treatment group were lower than those in the control group, with a statistically significant difference (P < 0.05). After treatment, the serum levels of Cys-C, TGF-β₁, and Hcy in two groups were lower than those before treatment (P < 0.05). The serum levels of Cys-C, TGF-β₁, and Hcy in the treatment group were lower than those in the control group (P < 0.05). Conclusion Puerarin Injection combined with Conbercept Ophthalmic Injection has clinical curative effect in treatment of non-proliferative diabetic retinopathy, can improve visual acuity, reduce the ocular sign, reduce the serum levels of Cys-C, TGF-β₁, and Hcy, with good safety.

R988.1

秦皇岛市科学技术研究与发展计划项目（201902A176）